Levi & Korsinsky announces that a class action lawsuit has been
commenced in the United States District Court for the District of New
Jersey on behalf of investors who purchased The Medicines Company
("Medicines" or the "Company") (NasdaqGS:MDCO) securities between
February 20, 2013 and February 12, 2014.
For more information, click here: http://zlk.9nl.com/the-medicines-company-mdco.
The complaint alleges that throughout the Class Period defendants made
false and/or misleading statements and/or failed to disclose matrial
information including but not limited to the following: (a) that
Medicine's drug candidate Cangrelor did not show superiority to
clopidogrel, a competing drug already approved by the Food and Drug
Administration, and (b) that Medicine's CHAMPION clinical trials were
unethically and inappropriately administered.
On February 12, 2014, the Food and Drug voted against approval of
Cangrelor for patients undergoing certain cardiovascular procedures.
If you suffered a loss in Medicines you have until April 22, 2014 to
request that the Court appoint you as lead plaintiff. Your ability to
share in any recovery doesn't require that you serve as a lead
plaintiff. To obtain additional information, contact Joseph E. Levi,
Esq. either via email at email@example.com
or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/the-medicines-company-mdco.
Levi & Korsinsky is a national firm with offices in New York, New
Jersey, Connecticut, and Washington D.C. The firm has extensive
expertise in prosecuting securities litigation involving financial
fraud, representing investors throughout the nation in securities and
shareholder lawsuits. Attorney advertising. Prior results do not
guarantee similar outcomes.
[ Back To NFVZone's Homepage ]